We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Dentsply (XRAY) Q1 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
In its upcoming report, Dentsply International (XRAY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.29 per share, reflecting a decline of 31% compared to the same period last year. Revenues are forecasted to be $851.55 million, representing a year-over-year decrease of 10.7%.
The current level reflects a downward revision of 1.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Dentsply metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Net sales- Connected Technology Solutions' will reach $233.14 million. The estimate indicates a year-over-year change of -5.6%.
Based on the collective assessment of analysts, 'Net sales- Wellspect Healthcare' should arrive at $74.82 million. The estimate points to a change of +5.4% from the year-ago quarter.
Analysts expect 'Net sales- Essential Dental Solutions' to come in at $352.85 million. The estimate indicates a year-over-year change of -3.1%.
Analysts' assessment points toward 'Net sales- Orthodontic and Implant Solutions' reaching $193.98 million. The estimate points to a change of -28.4% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Rest of World' should come in at $190.83 million. The estimate points to a change of -13.7% from the year-ago quarter.
The consensus estimate for 'Revenues- Europe' stands at $356.44 million. The estimate points to a change of -5.2% from the year-ago quarter.
Over the past month, shares of Dentsply have returned +5.6% versus the Zacks S&P 500 composite's +10.6% change. Currently, XRAY carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Dentsply (XRAY) Q1 Earnings: Wall Street's Insights on Key Metrics
In its upcoming report, Dentsply International (XRAY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.29 per share, reflecting a decline of 31% compared to the same period last year. Revenues are forecasted to be $851.55 million, representing a year-over-year decrease of 10.7%.
The current level reflects a downward revision of 1.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Dentsply metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Net sales- Connected Technology Solutions' will reach $233.14 million. The estimate indicates a year-over-year change of -5.6%.
Based on the collective assessment of analysts, 'Net sales- Wellspect Healthcare' should arrive at $74.82 million. The estimate points to a change of +5.4% from the year-ago quarter.
Analysts expect 'Net sales- Essential Dental Solutions' to come in at $352.85 million. The estimate indicates a year-over-year change of -3.1%.
Analysts' assessment points toward 'Net sales- Orthodontic and Implant Solutions' reaching $193.98 million. The estimate points to a change of -28.4% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Rest of World' should come in at $190.83 million. The estimate points to a change of -13.7% from the year-ago quarter.
The consensus estimate for 'Revenues- Europe' stands at $356.44 million. The estimate points to a change of -5.2% from the year-ago quarter.
View all Key Company Metrics for Dentsply here>>>
Over the past month, shares of Dentsply have returned +5.6% versus the Zacks S&P 500 composite's +10.6% change. Currently, XRAY carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>